Medicenna Therapeutics (OTCMKTS:MDNAF) Announces Earnings Results
by Tristan Rich · The Markets DailyMedicenna Therapeutics (OTCMKTS:MDNAF – Get Free Report) released its earnings results on Thursday. The company reported $999.00 EPS for the quarter, Zacks reports.
Medicenna Therapeutics Stock Up 2.2%
Shares of OTCMKTS MDNAF traded up $0.01 during midday trading on Thursday, reaching $0.29. The company’s stock had a trading volume of 92,467 shares, compared to its average volume of 70,244. Medicenna Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $1.43. The stock has a 50 day simple moving average of $0.37.
About Medicenna Therapeutics
Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.
Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.